started · updated
Rheumatoid arthritis research explores new therapies for non-responsive patients
New clinical research and reviews are addressing the challenges of treating rheumatoid arthritis, particularly for the 30 to 40 percent of patients who do not respond adequately to first-line biologics.
A review published in the journal Immunity & Inflammation highlights the potential of anti-inflammatory natural substances as therapeutic building blocks. However, the study notes that transitioning these substances into clinical practice remains difficult due to issues with standardization, bioavailability, and target assignment.
In parallel, Lynk Pharmaceuticals has released long-term results from its Phase III COURAGE-RA study regarding Zemprocitinib, a second-generation oral, selective JAK1 inhibitor. The study, which included 430 randomized adult patients, demonstrated significant efficacy over 76 weeks. By week 24, the drug met its primary endpoint, showing statistically significant superiority over a placebo according to American College of Rheumatology (ACR20) criteria. Long-term data showed sustained disease control, with high response rates maintained through the 76-week mark.
Entities
American College of Rheumatology · Immunity & Inflammation · Lynk Pharmaceuticals